P
Philippe Moreau
Researcher at University of Nantes
Publications - 693
Citations - 52995
Philippe Moreau is an academic researcher from University of Nantes. The author has contributed to research in topics: Multiple myeloma & Medicine. The author has an hindex of 104, co-authored 517 publications receiving 42530 citations. Previous affiliations of Philippe Moreau include University of Grenoble & National and Kapodistrian University of Athens.
Papers
More filters
Journal ArticleDOI
Multiple myeloma imaging.
Cyrille Touzeau,Philippe Moreau +1 more
TL;DR: With a CT scan and MRI, spinal compression can be detected or a surgical procedure planned, while MRI or a PET scan can be used to assess extension of the disease and the response to treatment.
Journal ArticleDOI
Outcomes for Asian patients with multiple myeloma receiving once- or twice-weekly carfilzomib-based therapy: a subgroup analysis of the randomized phase 3 ENDEAVOR and A.R.R.O.W. Trials.
Meletios A. Dimopoulos,Philippe Moreau,Shinsuke Iida,Shang-Yi Huang,Naoki Takezako,Wee Joo Chng,Wee Joo Chng,Anita Zahlten-Kumeli,Martina Sersch,Julia Li,Mei Huang,Jae Hoon Lee +11 more
TL;DR: Overall, carfilzomib had a favorable benefit-risk profile across both dosing regimens [once-weekly (Kd 70 mg/m2) and twice-weekly(Kd 56 mg/ m2)] in Asian patients with RRMM, which was consistent with the results of both parent studies.
Journal ArticleDOI
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation–positive hairy cell leukemia
Robert J. Kreitman,Philippe Moreau,Farhad Ravandi,Martin Hutchings,Anas Gazzah,Anne-Sophie Michallet,O. Wainberg,Alexander Stein,Sascha Dietrich,Maja J.A. de Jonge,Wolfgang Willenbacher,Jacques De Greve,Evgeny Arons,Palanichamy Ilankumaran,Paul Burgess,Eduard Gasal,Vivek Subbiah +16 more
TL;DR: Dabrafenib plus trametinib demonstrated durable responses with a manageable safety profile consistent with previous observations in other indications and should be considered as a rituximab-free therapeutic option for patients with relapsed/refractory BRAF V600E mutation-positive HCL.
Journal Article
Clinical and practical value of human cytomegalovirus DNAemia detection by semi-nested PCR for follow-up of BMT recipients.
Berthe-Marie Imbert-Marcille,Noel-Jean Milpied,M. Coste-Burel,B. Richet,Philippe Moreau,J-L Harousseau,Billaudel S +6 more
TL;DR: This study shows that DNAemia is a method that can replace viremia detection, allowing HCMV infection and disease follow-up of recipients of allogeneic BMT during the first year after BMT.
Journal ArticleDOI
Cost Effectiveness of Pegfilgrastim Versus Filgrastim After High-Dose Chemotherapy and Autologous Stem Cell Transplantation in Patients with Lymphoma and Myeloma
Lionel Perrier,Anne Lefranc,David Pérol,Philippe Quittet,Aline Schmidt-Tanguy,Carole Siani,Christian de Peretti,Bertrand Favier,Pierre Biron,Philippe Moreau,Jacques-Olivier Bay,Severine Lissandre,Fabrice Jardin,Daniel Espinouse,Catherine Sebban +14 more
TL;DR: Pegfilgrastim was less costly and less effective than fil grastim for the number of days with ANC <0.5 × 109/L avoided and the numberof days with platelets <50.0 ×-109/ L avoided, and the probability that filgrastIM dominated pegfil Grastim is 5 % for febrile neutropenia after conventional chemotherapy is 5.5%.